Show simple item record

Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

dc.contributor.authorZeuzem, Sen_US
dc.contributor.authorFoster, GRen_US
dc.contributor.authorWang, Sen_US
dc.contributor.authorAsatryan, Aen_US
dc.contributor.authorGane, Een_US
dc.contributor.authorFeld, JJen_US
dc.contributor.authorAsselah, Ten_US
dc.contributor.authorBourliere, Men_US
dc.contributor.authorRuane, PJen_US
dc.contributor.authorWedemeyer, Hen_US
dc.contributor.authorPol, Sen_US
dc.contributor.authorFlisiak, Ren_US
dc.contributor.authorPoordad, Fen_US
dc.contributor.authorChuang, W-Len_US
dc.contributor.authorStedman, CAen_US
dc.contributor.authorFlamm, Sen_US
dc.contributor.authorKwo, Pen_US
dc.contributor.authorDore, GJen_US
dc.contributor.authorSepulveda-Arzola, Gen_US
dc.contributor.authorRoberts, SKen_US
dc.contributor.authorSoto-Malave, Ren_US
dc.contributor.authorKaita, Ken_US
dc.contributor.authorPuoti, Men_US
dc.contributor.authorVierling, Jen_US
dc.contributor.authorTam, Een_US
dc.contributor.authorVargas, HEen_US
dc.contributor.authorBruck, Ren_US
dc.contributor.authorFuster, Fen_US
dc.contributor.authorPaik, S-Wen_US
dc.contributor.authorFelizarta, Fen_US
dc.contributor.authorKort, Jen_US
dc.contributor.authorFu, Ben_US
dc.contributor.authorLiu, Ren_US
dc.contributor.authorNg, TIen_US
dc.contributor.authorPilot-Matias, Ten_US
dc.contributor.authorLin, C-Wen_US
dc.contributor.authorTrinh, Ren_US
dc.contributor.authorMensa, FJen_US
dc.date.accessioned2018-02-08T09:40:31Z
dc.date.issued2018-01-25en_US
dc.date.submitted2018-01-31T10:31:44.491Z
dc.identifier.issn0028-4793en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/32126
dc.description.sponsorshipThe trials (NCT02604017, NCT02640157) were funded by AbbVie Inc.en_US
dc.format.extent354 - 369en_US
dc.relation.ispartofNEW ENGLAND JOURNAL OF MEDICINEen_US
dc.rightsFrom N Engl J Med, Zeuzem et al., Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection, 378:354-369. Copyright © 2018 Massachusetts Medical Society. Reprinted with permission.
dc.titleGlecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infectionen_US
dc.typeArticle
dc.rights.holderCopyright © 2018, Massachusetts Medical Society
dc.identifier.doi10.1056/NEJMoa1702417en_US
pubs.author-urlhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000423233400008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.issue4en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume378en_US


Files in this item

Thumbnail
Name:
Glecaprevir pibrentasvir NEJM ...
Size:
83.22Kb
Format:
application/
Description:
Accepted version
View/Open
Thumbnail
Name:
Zeuzem Glecaprevir–Pibrentasvir ...
Size:
1.058Mb
Format:
application/
Description:
Published version
View/Open

This item appears in the following Collection(s)

Show simple item record